Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:09:23 EDT Tue 08 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:IMUX - IMMUNIC INC - https://www.imux.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IMUX - Q0.212.74·13.430.712.74-0.37-2.8405.25,0462,95812.93  13.28  12.3517.43  5.06219:44:26Sep 0215 min RT 2¢

Recent Trades - Last 10 of 2958
Time ETExPriceChangeVolume
19:44:26Q12.92-0.1917
19:44:26Q12.92-0.1930
19:30:05Q12.74-0.371
19:30:05Q12.74-0.371
19:30:04Q12.74-0.371
19:30:04Q12.74-0.371
16:10:05Q12.74-0.371
16:10:05Q12.74-0.371
16:10:04Q12.74-0.371
16:10:04Q12.74-0.371

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-02 06:30U:IMUXNews ReleaseImmunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
2026-09-01 06:30U:IMUXNews ReleaseImmunic Appoints Chitrang Dave as Chief Data and Digital Officer
2026-08-11 06:30U:IMUXNews ReleaseImmunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-10 16:05U:IMUXNews ReleaseImmunic Appoints Elena Ridloff to Board of Directors
2026-07-09 06:30U:IMUXNews ReleaseImmunic to Participate in Investor Conferences in July
2026-06-10 06:30U:IMUXNews ReleaseImmunic to Participate in Investor, Industry and Scientific Conferences in June
2026-05-28 06:30U:IMUXNews ReleaseImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
2026-05-27 06:30U:IMUXNews ReleaseImmunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
2026-05-19 06:30U:IMUXNews ReleaseImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
2026-05-13 06:30U:IMUXNews ReleaseImmunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-30 06:30U:IMUXNews ReleaseImmunic to Participate in Investor and Medical Conferences in May
2026-04-28 06:30U:IMUXNews ReleaseImmunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
2026-04-23 08:00U:IMUXNews ReleaseImmunic, Inc. Announces 1-for-10 Reverse Stock Split
2026-04-09 06:30U:IMUXNews ReleaseImmunic to Participate in Scientific and Medical Conferences in April
2026-04-01 06:30U:IMUXNews ReleaseImmunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-03-31 06:30U:IMUXNews ReleaseImmunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
2026-03-10 06:30U:IMUXNews ReleaseImmunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
2026-03-03 06:30U:IMUXNews ReleaseImmunic to Participate in Investor Conferences in March
2026-02-26 06:30U:IMUXNews ReleaseImmunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
2026-02-17 16:05U:IMUXNews ReleaseImmunic Announces Closing of Oversubscribed Private Placement Financing